MoonLake Immunotherapeuti... (MLTX)
NASDAQ: MLTX
· Real-Time Price · USD
54.95
0.07 (0.13%)
At close: Aug 15, 2025, 10:00 AM
0.13% (1D)
Bid | 54.8 |
Market Cap | 3.49B |
Revenue (ttm) | 101.85K |
Net Income (ttm) | -176.47M |
EPS (ttm) | -2.79 |
PE Ratio (ttm) | -19.7 |
Forward PE | -13.04 |
Analyst | Buy |
Ask | 55.48 |
Volume | 29,555 |
Avg. Volume (20D) | 531,487 |
Open | 54.88 |
Previous Close | 54.88 |
Day's Range | 54.53 - 55.30 |
52-Week Range | 31.42 - 58.26 |
Beta | 1.27 |
About MLTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MLTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MLTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+17.95%
MoonLake Immunotherapeutics shares are trading hig...
Unlock content with
Pro Subscription
2 months ago
+5.51%
MoonLake Immunotherapeutics shares are trading higher following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.

2 months ago · seekingalpha.com
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestMoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is...